[{"orgOrder":0,"company":"Procare Pharmaceutical","sponsor":"Biovaxys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"BVX-0918C","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Procare Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Procare Pharmaceutical \/ Procare Health","highestDevelopmentStatusID":"4","companyTruncated":"Procare Pharmaceutical \/ Procare Health"}]

Find Clinical Drug Pipeline Developments & Deals by Procare Pharmaceutical

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : BioVaxys’s cancer vaccine BVX-0918C, created by extracting a patient’s own cancer cells, chemically treating them with a hapten, and re-injecting them into patient to induce an immune response to proteins which are otherwise not immunogenic.

                          Brand Name : BVX-0918C

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          May 02, 2022

                          Lead Product(s) : BVX-0918C

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Biovaxys

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank